Previous studies found that pre-existing T790M may exist in many TKI-naive NSCLCs, and may become the dominant tumor population as a result of drug pressure in EGFR TKIs resistant NSCLC patients (31). This evidence concerns the gene EGFR and non-small cell lung carcinoma.